Owl Peak Labs

Owl Peak Labs

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Owl Peak Labs is pioneering a novel diagnostic approach for early colorectal cancer detection using infrared thermal imaging. The company's SpectraGI platform captures subtle temperature and biochemical shifts in tissue, aiming to identify malignancies long before they are visible with traditional methods like colonoscopy. This technology has the potential to shift screening from reactive diagnosis to proactive prevention, significantly improving patient outcomes. As a private, pre-revenue diagnostics firm, Owl Peak is focused on developing and validating its platform for clinical use.

OncologyGastroenterology

Technology Platform

Infrared spectral thermal imaging platform (SpectraGI) that detects metabolic heat patterns associated with cancerous and precancerous tissue in the gastrointestinal tract.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The large and growing global colorectal cancer screening market presents a significant opportunity.
Integration into the existing colonoscopy workflow offers a clear adoption path.
Successful validation in CRC could allow platform expansion into other GI cancers.

Risk Factors

High clinical risk that thermal signatures are not sufficiently reliable for diagnosis.
Faces intense competition from other advanced endoscopic imaging technologies.
Must navigate regulatory clearance and secure insurance reimbursement.

Competitive Landscape

Competes in the enhanced endoscopy space against companies offering narrow-band imaging (Olympus), confocal laser endomicroscopy (Mauna Kea Technologies), and AI-based polyp detection software (Medtronic, Cosmo Pharmaceuticals). Must differentiate on the basis of unique metabolic data.